Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7529444 | 0.84 | KDM4E (0.39) | POLBL3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL28242652 | 0.82 | — | — | |
| SCHEMBL24997068 | 0.82 | POLB (0.52) | NPSR1POLBL3MBTL1KDM4EHSD17B10 | |
| SCHEMBL8341632 | 0.82 | POLB (0.52) | NPSR1POLBL3MBTL1KDM4EHSD17B10 | |
| SCHEMBL477208 | 0.81 | TDP1 (0.41) | NPSR1KDM4EKMT2AALDH1A1TSHR | |
| SCHEMBL8442784 | 0.80 | KMT2A (0.51) | NPSR1POLBL3MBTL1KDM4EHSD17B10 | |
| SCHEMBL10263618 | 0.76 | MEN1 (0.47) | NPSR1POLBL3MBTL1KDM4EKMT2A | |
| SCHEMBL1648136 | 0.75 | POLB (0.48) | NPSR1POLBL3MBTL1KDM4EHSD17B10 | |
| SCHEMBL772416 | 0.74 | GAA (0.38) | NPSR1POLBKDM4EKMT2AALDH1A1 | |
| SCHEMBL10436830 | 0.73 | ALDH1A1 (0.51) | NPSR1POLBL3MBTL1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | claimed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | claimed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | claimed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | claimed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | NPSR1 3973/4885POLB 77/4885L3MBTL1 4435/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | NPSR1 3973/4885POLB 77/4885L3MBTL1 4435/4885 |
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | NPSR1 4786/4885POLB 12/4885L3MBTL1 220/4885 |
| US-20090306054-A1 | INTEGRASE INHIBITORS | TYMP, POLR2E, CCNI | NPSR1 4780/4885POLB 7/4885L3MBTL1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.